| gap-debate-20260411- | Which scaffold protein interaction changes represent druggable therapeutic targe | open | 0.79 | 0.68 | 2026-04-11 | 0 | | neurodegeneration |
| gap-debate-20260411- | How do mitochondrial protein alterations at synapses correlate with cognitive de | open | 0.82 | 0.67 | 2026-04-11 | 0 | | neurodegeneration |
| gap-debate-20260411- | What are the specific PTM changes in synaptic vesicle proteins during early AD p | partially_addressed | 0.88 | 0.70 | 2026-04-11 | 0 | | neurodegeneration |
| gap-debate-20260411- | What specific white matter tract degeneration patterns measured by DTI correlate | open | 0.75 | 0.66 | 2026-04-11 | 0 | | neurodegeneration |
| gap-debate-20260411- | How can connectomic biomarkers be validated for accurate AD staging and progress | open | 0.80 | 0.70 | 2026-04-11 | 0 | | neurodegeneration |
| gap-debate-20260411- | What are the causal relationships between sleep-wake disruption, thalamic connec | resolved | 0.85 | 0.70 | 2026-04-11 | 0 | | neurodegeneration |
| gap-debate-20260411- | How can functional hyperconnectivity patterns distinguish compensatory mechanism | partially_addressed | 0.90 | 0.71 | 2026-04-11 | 0 | | neurodegeneration |
| gap-debate-20260411- | What is the therapeutic window for peripheral immune modulation to prevent CNS d | open | 0.75 | 0.68 | 2026-04-11 | 0 | | immunology |
| gap-debate-20260411- | How does gut microbiome dysbiosis mechanistically drive CNS neurodegeneration in | resolved | 0.80 | 0.69 | 2026-04-11 | 0 | | neurodegeneration |
| gap-debate-20260411- | Can peripheral cytokine signatures reliably predict CNS pathology progression in | resolved | 0.85 | 0.70 | 2026-04-11 | 0 | | immunology |
| gap-debate-20260411- | What are the specific molecular mechanisms by which peripheral monocytes cross t | partially_addressed | 0.90 | 0.68 | 2026-04-11 | 0 | | neurodegeneration |
| gap-debate-20260411- | What is the temporal relationship between lipid metabolism alterations and class | open | 0.73 | 0.71 | 2026-04-11 | 0 | | neurodegeneration |
| gap-debate-20260411- | Which specific phosphoinositide signaling nodes are most critical for neuronal s | open | 0.75 | 0.65 | 2026-04-11 | 0 | | cell-biology |
| gap-debate-20260411- | How can ABCA1 modulators achieve brain selectivity to avoid peripheral cholester | open | 0.78 | 0.71 | 2026-04-11 | 0 | | drug-development |
| gap-debate-20260411- | What determines optimal GM1/GM3 ganglioside ratios for preventing amyloid nuclea | open | 0.82 | 0.69 | 2026-04-11 | 0 | | neurodegeneration |
| gap-debate-20260411- | Can phase separation kinetics be measured and modulated in vivo to assess therap | open | 0.70 | 0.67 | 2026-04-11 | 0 | | biophysics |
| gap-debate-20260411- | Why do G-quadruplex RNA structures in C9orf72 repeats resist antisense oligonucl | open | 0.75 | 0.69 | 2026-04-11 | 0 | | structural-biology |
| gap-debate-20260411- | What are the specific cellular targets that arginine-rich DPRs bind to disrupt n | open | 0.80 | 0.70 | 2026-04-11 | 0 | | molecular-biology |
| gap-debate-20260411- | Do nuclear import enhancers reduce or exacerbate nuclear TDP-43 aggregation in c | resolved | 0.85 | 0.71 | 2026-04-11 | 0 | | neurodegeneration |
| gap-pubmed-20260410- | How does clusterin dysregulation mechanistically contribute to late-onset Alzhei | open | 0.83 | 0.00 | 2026-04-10 | 0 | | neurodegeneration |
| gap-pubmed-20260410- | What determines clusterin's selectivity for different misfolded proteins (amyloi | open | 0.79 | 0.00 | 2026-04-10 | 0 | | neurodegeneration |
| gap-pubmed-20260410- | How do clusterin's hydrophobic tails maintain accessibility for chaperone functi | open | 0.80 | 0.00 | 2026-04-10 | 0 | | neurodegeneration |
| gap-pubmed-20260410- | What determines the relative contribution of dietary vs endogenous kynurenines t | open | 0.74 | 0.00 | 2026-04-10 | 0 | | neurodegeneration |
| gap-pubmed-20260410- | How do dietary kynurenines cross the blood-brain barrier and affect neurodegener | resolved | 0.80 | 0.00 | 2026-04-10 | 0 | | neurodegeneration |
| gap-pubmed-20260410- | What determines the threshold for mitochondrial calcium overload that triggers p | open | 0.72 | 0.00 | 2026-04-10 | 0 | | neurodegeneration |
| gap-pubmed-20260410- | Does NCLX activation provide therapeutic benefit in sporadic Parkinson's disease | open | 0.76 | 0.00 | 2026-04-10 | 0 | | neurodegeneration |
| gap-pubmed-20260410- | How does PINK-1 deficiency mechanistically lead to NCLX inhibition and delayed c | open | 0.80 | 0.00 | 2026-04-10 | 0 | | neurodegeneration |
| gap-pubmed-20260410- | What are the optimal outcome measures for GLP-1R agonist trials in multiple scle | open | 0.76 | 0.00 | 2026-04-10 | 0 | | neurodegeneration |
| gap-pubmed-20260410- | Why does NLY01 efficacy depend on cuprizone delivery method despite consistent d | open | 0.80 | 0.00 | 2026-04-10 | 0 | | neurodegeneration |
| gap-pubmed-20260410- | Do other ECM proteins beyond FN1 and COL6A2 contribute to protection against APO | open | 0.78 | 0.00 | 2026-04-10 | 0 | | neurodegeneration |
| gap-pubmed-20260410- | How does pathological FN1 accumulation at the BBB impair toxic protein clearance | open | 0.80 | 0.00 | 2026-04-10 | 0 | | neurodegeneration |
| gap-pubmed-20260410- | What molecular mechanisms explain how FN1 loss-of-function variants protect agai | open | 0.85 | 0.00 | 2026-04-10 | 0 | | neurodegeneration |
| gap-pubmed-20260410- | How do metabolic disorder corrections in the gut translate to improved neurologi | open | 0.76 | 0.00 | 2026-04-10 | 0 | | neurodegeneration |
| gap-pubmed-20260410- | Which of the 26 identified rhubarb components are responsible for the neuroprote | open | 0.79 | 0.00 | 2026-04-10 | 0 | | neurodegeneration |
| gap-pubmed-20260410- | What specific molecular mechanisms link gut microbiota changes to blood-brain ba | open | 0.80 | 0.00 | 2026-04-10 | 0 | | neuroinflammation |
| gap-pubmed-20260410- | How do diabetes-AD comorbidity mechanisms inform GLP-1 agonist therapeutic strat | open | 0.74 | 0.00 | 2026-04-10 | 0 | | neurodegeneration |
| gap-pubmed-20260410- | What are the specific molecular mechanisms by which GLP-1 receptor agonists exer | open | 0.80 | 0.00 | 2026-04-10 | 0 | | neurodegeneration |
| gap-pubmed-20260410- | How does MLKL transition from auto-inhibited to membrane-embedded state? | open | 0.79 | 0.00 | 2026-04-10 | 0 | | neurodegeneration |
| gap-pubmed-20260410- | What determines species-specific differences in MLKL activation mechanisms? | open | 0.77 | 0.00 | 2026-04-10 | 0 | | neurodegeneration |
| gap-pubmed-20260410- | What biological markers can reliably distinguish regressive from non-regressive | open | 0.72 | 0.00 | 2026-04-10 | 0 | | neurodegeneration |
| gap-pubmed-20260410- | Why does carnitine correlate with stereotypic behaviors in ASD despite showing n | open | 0.74 | 0.00 | 2026-04-10 | 0 | | neurodegeneration |
| gap-pubmed-20260410- | What mechanisms link elevated C22 VLCFA levels to autism pathophysiology and why | open | 0.77 | 0.00 | 2026-04-10 | 0 | | neurodegeneration |
| gap-pubmed-20260410- | Do GLP-1 agonists' neuroprotective effects translate from animal models to human | open | 0.82 | 0.00 | 2026-04-10 | 0 | | neurodegeneration |
| gap-pubmed-20260410- | What are the specific molecular mechanisms by which GLP-1 receptor agonists modu | open | 0.80 | 0.00 | 2026-04-10 | 0 | | neuroinflammation |
| gap-pubmed-20260410- | Why does hepatic steatosis persist despite improved hepatic gene expression prof | open | 0.73 | 0.00 | 2026-04-10 | 0 | | neurodegeneration |
| gap-pubmed-20260410- | What mechanisms link peripheral metabolic improvements to enhanced brain synapti | open | 0.77 | 0.00 | 2026-04-10 | 0 | | neurodegeneration |
| gap-pubmed-20260410- | How does FTO inhibition increase brain m6A methylation when FTO is an m6A demeth | open | 0.79 | 0.00 | 2026-04-10 | 0 | | neurodegeneration |
| gap-pubmed-20260410- | Do common LRRK2 PD mutations affect antimicrobial defense and mitochondrial teth | resolved | 0.86 | 0.00 | 2026-04-10 | 0 | | neurodegeneration |
| gap-pubmed-20260410- | What molecular mechanisms enable LRRK2 to scaffold the RAB32-ACOD1 complex for i | open | 0.80 | 0.00 | 2026-04-10 | 0 | | neurodegeneration |
| gap-pubmed-20260410- | How does LRRK2's antimicrobial function relate to its role in Parkinson's diseas | open | 0.85 | 0.00 | 2026-04-10 | 0 | | neurodegeneration |